Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Ventriculoperitoneal (VP) Shunt Placement
Treatment for Neural tube defects
Typical Dosage: N/A (surgical procedure)
Effectiveness
90%
Safety Score
55%
Clinical Trials
500
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
N/A (surgical procedure)
Time to Effect
Immediate
Treatment Duration
Lifetime (requires ongoing management and potential revisions)
Evidence Quality
HIGHNumber Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,500
Side Effect Mgmt:$5,000
Total Annual:$46,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
12
Outcome-Based Costs
Cost per Responder
$48,947.37
Ventriculoperitoneal (VP) Shunt Placement Outcomes
for Neural tube defects
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+95%
Common Side Effects
Shunt malfunction (occlusion, disconnection)
+35%
Shunt infection
+10%
Overdrainage (slit ventricle syndrome)
+7%
Seizures
+7%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov